<DOC>
	<DOC>NCT02253992</DOC>
	<brief_summary>The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.</brief_summary>
	<brief_title>Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com For Dose Escalation: Subjects with any previously treated advanced (metastatic or refractory) solid tumor type and Bcell nonHodgkin lymphoma For Cohort Expansion: Subjects must have a previously treated advanced solid tumor or B cell nonHodgkin's lymphoma to be eligible Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 For certain subjects, willing and able to provide pretreatment and ontreatment fresh tumor biopsy Women of childbearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men Known central nervous system metastases or central nervous system as the only source of disease Other concomitant malignancies (with some exceptions per protocol) Active, known or suspected autoimmune disease Uncontrolled or significant cardiovascular disease History of hepatitis (B or C) History of active or latent tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>